Strategic acquisition expands global analytical capabilities

Specac Ltd, a portfolio company of Ampersand Capital Partners and a leading provider of spectroscopy accessories and sample preparation solutions, has acquired Amax Precision Ltd (Amax), a global leader in precision contract manufacturing for analytical instruments.

The acquisition strengthens the Group’s manufacturing and technological capabilities, enhancing its ability to serve OEM partners worldwide and broadening its presence in the life sciences sector. Amax brings expertise in high-precision engineering, advanced assembly, and testing capabilities. When combined with Specac’s module-based assembly and design-driven solutions, the integration provides greater vertical integration and a comprehensive service offering. Together, the companies employ over 400 people across three continents and maintain a significant footprint co-located with client production and engineering sites.

“Joining Specac opens an exciting new chapter for us,” said Thomas Chen, Chairman of Amax. “It provides access to new global markets and supports our long-term growth strategy as we aim to take our capabilities to the next level.”

Mark Dearden, President and CEO of Specac Group, added: “This acquisition enables us to offer an expanded range of capabilities to existing customers and strengthens our position as a leading OEM partner for analytical instrumentation.”

Dave Patteson, Partner at Ampersand Capital, commented: “The integration of Amax into the Specac Group significantly increases scale, enhances client offerings, and boosts contributions to life sciences. Both companies bring complementary strengths, multi-decade client relationships, and proven technical leadership.”

More information online